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article under the CC BY-NC-ND licenseAbstract Systemic therapy for metastatic renal cell carcinoma (mRCC) has evolved drasti-
cally, with agents targeting vascular endothelial growth factor (VEGF) and the mammalian
target of rapamycin (mTOR) now representing a standard of care. The present paper is to re-
view the current status of relevant clinical trials that were either recently completed or
ongoing. (1) Though observation remains a standard of care following resection of localized
disease, multiple trials are underway to assess VEGF- and mTOR-directed therapies in this
setting. (2) While the preponderance of retrospective data favors cytoreductive nephrectomy
in the context of targeted agents, prospective data to support this approach is still forth-
coming. (3) The first-line management of mRCC may change substantially with multiple studies
exploring vaccines, immune checkpoint inhibitors, and novel targeted agents currently under-
way. In general, prospective studies that will report within the next several years will be crit-
ical in defining the role of adjuvant therapy and cytoreductive nephrectomy. Over the same
span of time, the current treatment paradigm for first-line therapy may evolve.
ª 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Systemic therapy for metastatic renal cell carcinoma
(mRCC) has evolved markedly in recent years, due in large
part to a better understanding of RCC biology. In 50%e75%Pal).
f Chinese Urological Association a
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(http://creativecommons.org/liof patients, aberrations in the von Hippel Lindau (VHL) gene
leads to increased expression of hypoxia inducible factor-a
(HIF-a) [1]. HIF-a expression in turn drives an increase in
vascular endothelial growth factor (VEGF). Through down-
stream signaling via the mammalian target of rapamycinnd SMMU.
n and hosting by Elsevier (Singapore) Pte Ltd. This is an open access
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Table 1 Completed and ongoing adjuvant trials of VEGF-
TKIs and mTOR inhibitors in RCC.
Trial
(sponsor)
Sponsor Agent assessed n Completion
(projected
or actual)
ASSURE ECOG Sunitinib/sorafenib 1943 Sep 2010
ATLAS Pfizer Axitinib 592 June 2017
EVEREST SWOG Everolimus 1218 Oct 2021
PROTECT GSK Pazopanib 1500 April 2016
SORCE MRC Sorafenib 1420 Dec 2012
S-TRAC Pfizer Sunitinib 720 Nov 2015
VEGF-TKIs, vascular endothelial growth factor (VEGF)-tyrosine
kinase inhibitors; mTOR, mammalian target of rapamycin; RCC,
renal cell carcinoma.
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Translating these findings from bench to bedside, there are
multiple inhibitors of VEGF and mTOR that are now clini-
cally utilized. Small molecule VEGF-tyrosine kinase in-
hibitors (VEGF-TKIs) that have shown clinical benefit in
phase III trials include sunitinib, sorafenib, pazopanib and
axitinib, and the monoclonal antibody bevacizumab (in
combination with interferon-a [IFN-a]) has similarly shown
benefit in a phase III trial in the front-line setting [2e5].
Two mTOR inhibitors (temsirolimus and everolimus) have
also garnered FDA approval on the basis of positive phase III
data [6,7].
The utilization of these agents brings up several key is-
sues in multidisciplinary management. For instance, in
other disease states (e.g., breast cancer and colorectal
cancer), systemic therapies frequently transition from the
metastatic to adjuvant setting. Multiple studies to evaluate
VEGF-TKIs and mTOR inhibitors as adjuvant treatment are
underway, but at the present time, the standard of care
following nephrectomy remains observation [8]. A second
multidisciplinary issue is the use of cytoreductive ne-
phrectomy in patients with synchronous metastases.
Although prospective trials have firmly established the role
of this procedure in the context of immune-based therapies
(e.g., IFN-a and interleukin-2 [IL-2]), it is unclear whether
cytoreductive nephrectomy is essential in patients with
synchronous metastases receiving targeted therapies [9].
Finally, although implementation of systemic therapy for
metastatic disease typically takes place in the medical
oncology clinic, the evolving healthcare landscape in mul-
tiple countries may frequently necessitate involvement of
the urologist.
The current review provides a framework for
approaching these multidisciplinary issues in RCC manage-
ment. The status of adjuvant therapy trials is discussed,
along with trials and retrospective data addressing the role
of cytoreductive nephrectomy. Finally, recent innovations
in therapy for mRCC are discussed e given the scope and
intent of this review, discussion is largely focused on front-
line management.
2. Evidence acquisition
A Medline database search was conducted from the years
2000e2014 using the following search terms: “adjuvant
therapy (of) renal cell carcinoma”, “cytoreductive ne-
phrectomy”, and “systemic therapy (for) metastatic renal
cell carcinoma”. An identical search was performed using
the American Society of Clinical Oncology Abstract data-
base. Search results were filtered to exclude review arti-
cles, editorials and letters. Prospective and retrospective
studies were retained. Trials in progress or recently
completed that were relevant to the current manuscript
were identified through a search of Clinicaltrials.gov.
3. Evidence synthesis
3.1. Current status of adjuvant therapy for RCC
The concept of exploring systemic treatments for RCC in
the adjuvant setting is not new e multiple prospectivestudies were completed in the immunotherapy era. Several
notable examples include a study by the Eastern Coopera-
tive Oncology Group (ECOG), in which 283 patients with
pT3-4aN0M0 or pTxN1-3M0 RCC were randomized to receive
IFN-a for a period of 6 months or observation [10]. Inter-
estingly, this study showed a higher 5-year overall survival
(OS) with observation as compared to IFN-a (62% vs. 51%,
p Z 0.09). An Italian study employed a similar randomiza-
tion in patients with high-risk localized RCC and similarly
showed no significant improvement in clinical outcome with
adjuvant IFN-a [11]. IL-2 has also been assessed as an
adjuvant. The Cytokine Working Group (CWG) conducted a
study in which patients received 1 cycle of high-dose IL-2 or
observation [12]. A futility analysis conducted after
enrollment of 69 patients led to early closure after it was
determined the study would not be able to achieve its
primary endpoint of improving 2-year disease-free survival
(DFS).
Failed attempts at proving clinical benefit with adjuvant
immunotherapy have not stifled efforts to explore targeted
therapies in the same setting (Table 1). The largest study to
date exploring adjuvant targeted therapy is the ASSURE
trial (ECOG 2805), which has completed accrual of 1943
patients [13]. Patients were randomized to receive either
sunitinib, sorafenib or placebo for a duration of 1 year, with
stratification by histology and ECOG performance status.
Although efficacy data from this study is still forthcoming, a
cardiac substudy from ASSURE has been reported [14]. Se-
rial assessments of ejection fraction (EF) suggested no
significant decline with sunitinib or sorafenib as compared
to placebo. Notably, concerns for cardiac toxicity with
these agents have emerged in the metastatic setting [15].
Several other studies are exploring the role of sunitinib
and sorafenib in the adjuvant setting. The SORCE trial
accrued a total of 1711 patients across western Europe and
Australia, and randomized patients with an intermediate or
high Leibovich score to either sorafenib for 3 years, sor-
afenib for 1 year followed by placebo for 2 years, or pla-
cebo for 3 years [16]. Although efficacy data is still
forthcoming, the SORCE investigators have reported key
demographic and clinicopathologic data from their trial
[17]. Notably, 182 patients (10.6%) had pT1b disease, and
21% of patients had pT2 disease. Thus, although the study
was intended to encompass a group of at-risk patients, a
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low frequency of anticipated events in this subset could
have implications in terms of the likelihood of SORCE
meeting its primary endpoint (improvement in DFS).
Approximately 42% of patients had an open nephrectomy,
while the remainder had a laparoscopic procedure. With
this roughly even divide, SORCE may also provide key in-
sights into the impact of surgical technique on the efficacy
of adjuvant therapy.
In contrast to SORCE, the S-TRAC study will randomize
720 patients with high-risk disease using the UCLA Inte-
grated Staging System to either sunitinib or placebo for 1
year [18]. Outside of sunitinib and sorafenib, there are two
studies investigating distinct VEGF-TKIs. In the PROTECT
trial, a total of 1500 patients with pT2N0M0 (Fuhrman grade
3e4), pT3-4N0M0, or pTxN1M0 received either pazopanib or
placebo for a total of 1 year. The ATLAS trial is an ongoing
effort in which 592 patients with pT2-4N0M0 or pTxN1M0
RCC will receive axitinib or placebo over the span of 3
years.
A common thread amongst most of the adjuvant trials of
VEGF-TKIs is difficulties in dosing. In the ASSURE trial, the
starting doses of sunitinib and sorafenib had to be reduced
from conventional doses used in the metastatic setting. If
patients tolerated a lowered dose during the first two cy-
cles of therapy, the dose was subsequently escalated. The
SORCE and PROTECT studies also similarly required a
reduction in the starting dose of sorafenib and pazopanib,
respectively. To explain the difference in tolerability of
adjuvant treatment, one might posit that patients with
localized disease may have a different biology as compared
to patients with metastatic disease. However, a more likely
explanation is that patients receiving adjuvant therapy may
have a lower threshold for accepting toxicity for the end
result of lowering the rate of disease recurrence. In
contrast, patients with metastatic disease may be willing to
tolerate a higher level of toxicity to combat further disease
progression.
Two other trials of targeted therapy in the adjuvant
setting deserve mention. In the EVEREST trial, a total of
1218 patients with pT1bN0M0 (Fuhrman grade 3e4) or pT2-
4N1-3M0 disease will be randomized to either everolimus or
placebo for 1 year [19]. The study has completed roughly
half of its anticipated accrual. A second study evaluating
the carbonic anhydrase IX (CAIX)-directed antibody gir-
entuximab has recently been reported. CAIX has been
related to RCC pathogenesis and may be a biomarker of
response to VEGF-directed agents [20,21]. In a phase III
trial, 864 patients with pT2NxM0 (Fuhrman grade 3e4),
pT3-4NxM0 or PTxN1M0 disease were randomized to receive
loading with girentuximab followed by 23 weekly intrave-
nous doses or placebo for the same duration of time [22].
Ultimately, the study failed to achieve its primary endpoint
of demonstrating an improvement in DFS. Notably, the
study did identify that patients with high levels of CAIX in
nephrectomy tissue derived clinical benefit with girentux-
imab. These findings suggest a potential path for further
development of adjuvant girentuximab in a population of
patients selected by high CAIX expression.
Finally, a discussion of adjuvant therapy is not complete
without noting the highest-risk group of patients e those
individuals that have had metastasectomy for limited sitesof metastatic disease [23]. Across multiple series, 5-year
survival rates in this population vary from 13% to 50%
[24]. Although the standard of care following meta-
stasectomy remains vigilant imaging, one study (ECOG
2810) aims to assess the role of targeted therapy in this
setting. Specifically, this phase III trial will randomize a
total of 180 patients with complete resection of metastatic
disease to 1 year of either pazopanib or placebo, with the
primary endpoint of DFS.3.2. Current status of cytoreductive nephrectomy
for mRCC
In the era of immunotherapy, the role of cytoreductive was
well established. In two identical protocols, 331 patients
were randomized to receive IFN-a alone or with cytore-
ductive nephrectomy [25]. Median OS was 13.6 months in
patients receiving cytoreductive nephrectomy, as
compared to 7.8 months in the IFN-a alone group
(p Z 0.0002). Correlative studies examining patients who
have received cytoreductive nephrectomy show fluxes in
certain immune subpopulations following the procedure,
such as an increase in natural killer (NK) cells [26]. These
changes provide a plausible mechanism for synergy be-
tween immunotherapy and surgery.
In the setting of targeted therapies, the role of cytore-
ductive nephrectomy remains unclear. At present, the
practicing urologist must rely largely on retrospective data.
An analysis of the Surveillance, Epidemiology and End Re-
sults (SEER) database suggested that median OS amongst
patients receiving cytoreductive nephrectomy improved
from 13 months to 19 months between the time periods of
1993e2004 and 2005e2010, respectively [27]. In patients
who did not receive cytoreductive nephrectomy, no sig-
nificant difference in OS was noted between the two time
periods. Notably, the latter period was thought to reflect
the targeted therapy era, given that FDA approvals of
VEGF- and mTOR-directed agents occurred over this period.
A similar interpretation of the SEER data suggesting
improved survival with cytoreductive nephrectomy in
recent years has been confirmed by other groups [28,29].
Strengths of the SEER database include its size, encom-
passing nearly 28% of the US population. However, a major
limitation is that the database does not provide treatment-
related information e thus, the nature of therapy rendered
during the two time periods assessed (e.g., targeted ther-
apy vs. immunotherapy) is merely an assumption.
A more recent retrospective study reported by the In-
ternational mRCC Database Consortium provides more
granular, patient-level data in a cohort of individuals who
had received targeted therapy for mRCC [30]. This data-
base houses records for a total of 1658 patients with syn-
chronous metastatic disease, of whom 982 had
cytoreductive nephrectomy. The survival benefit associated
with the procedure was profound (20.6 months vs. 9.5
months; p < 0.0001). A challenge in interpreting this data is
an inherent selection bias, as patients may have not
received cytoreductive nephrectomy on account of
comorbidities or poor performance status. However, even
after adjustment for standard prognostic criteria, the
hazard ratio for death with cytoreductive nephrectomy was
22 S.K. Pal et al.0.60 (95%CI, 0.52e0.69; p < 0.0001). A key finding from the
study was that patients with a poor prognosis (specifically,
those patients with a projected OS of <12 months)
appeared to derive no benefit from the procedure.
Although these findings require further validation, they
provide perhaps the most robust justification to date for
continued use of cytoreductive nephrectomy in patients
receiving targeted therapy, perhaps with the exception of
patients with poor prognostic criteria.
Two prospective trials are currently underway to assess
the utility and timing of cytoreductive nephrectomy,
respectively. In the French-led CARMENA trial, a total of
576 patients will be randomized to receive either sunitinib
alone or cytoreductive nephrectomy [31]. The primary
endpoint of the trial is OS, with secondary endpoints
including post-operative morbidity and non-compliance
with sunitinib therapy. In EORTC 30073, patients will be
randomized to receive either sunitinib followed by cytore-
ductive nephrectomy, or cytoreductive nephrectomy fol-
lowed by sunitinib [32]. The study will enroll a total of 458
patients, and will examine the primary endpoint of PFS.
Although both CARMENA and EORTC 30073 will provide
valuable insights, the studies do suffer from some inherent
limitations. Perhaps most importantly, both studies are
based on sunitinib. In the current landscape, it is unclear
whether the results will be applicable to other potential
first-line agents, such as bevacizumab, pazopanib or tem-
sirolimus. Furthermore, with multiple other relevant agents
evolving (as discussed in the next section), it is possible
that the study results will be antiquated by the time they
are available.
3.3. Current status of first-line therapy for mRCC
National Comprehensive Cancer Network (NCCN) guidelines
offer several category 1 (i.e., unanimous) recommenda-
tions for first-line systemic therapy for mRCC. These
include sunitinib, pazopanib and bevacizumab with IFN-a,
or temsirolimus in the setting of poor-risk features [33].
Each of these agents is supported by phase III data which
has been reviewed extensively in the existing literature. In
the clinic, the practicing physician is faced with theTable 2 Planned, ongoing and recently completed trials explor
Experimental arm Control arm n
Phase II trials
Cabozantinib Sunitinib 150
MPDL3280A  Bevacizumab Sunitinib 150
Phase III trials
Sunitinib þ IMA901 þ cyclophosphamide Sunitinib 320
Sunitinib þ AGS-003 Sunitinib 450
Nivolumab þ ipilimumab a a
a Details not publicly available.
b Final data collection date for primary outcome measure.challenge of deciding amongst these agents. Comparative
data have emerged in recent years which compare two
frequently utilized front-line options, sunitinib and pazo-
panib. In the COMPARZ trial, 1110 patients with mRCC and
no prior treatment were randomized to receive either
sunitinib or pazopanib at standard doses [34]. The primary
endpoint of the trial was PFS, with secondary endpoints
including OS, quality of life (QoL) and safety.
Ultimately, pazopanib was determined to be non-
inferior to sunitinib with respect to PFS (HR 1.05, 95%CI
0.90e1.22) [34]. No significant difference in OS was
observed across treatment arms. The COMPARZ trial offers
a unique opportunity to compare the side effect profile of
two distinct VEGF-TKIs. Sunitinib was found to be associ-
ated with a greater incidence of fatigue, hand-foot syn-
drome and thrombocytopenia, while pazopanib was found
to have a great incidence of transaminitis. QoL assessments
performed during the first 6 months of therapy generally
favored pazopanib. Of note, however, these assessments
were performed at day 28 of each 42-day cycle. In the
context of sunitinib therapy, which is dosed on a 4 week on/
2 week off schedule, day 28 would presumably be when
toxicity peaks. In contrast, treatment with pazopanib re-
mains consistent across the entire 42-day cycle e thus, QoL
metric may be somewhat biased in this report.
COMPARZ provides an important benchmark for OS es-
timates in mRCC. Whereas a median OS of approximately 13
months was quoted in the cytokine era, median OS was 28.3
months and 29.1 months in the pazopanib and sunitinib
arms, respectively [35,36]. In the subset of patients with
good-risk disease by MSKCC risk criteria, median OS was
42.5 months with pazopanib and 43.6 months with suniti-
nib. These impressive statistics are critical to factor into
forthcoming clinical trials, particularly studies of immuno-
therapy which hope to demonstrate OS improvement as a
primary endpoint.
The practicing urologist should be aware of several
studies that may substantially alter the current approach
to first-line management (Table 2). Two phase III trials are
exploring VEGF-TKI therapy in combination with cancer
vaccines. The first explores IMA901, a vaccine comprised
of tumor associated peptides (TUMAPs) identified throughing novel therapies for mRCC in the front-line setting.
Primary
endpoint
Status
PFS Enrollment ongoing
(Estimated primary completion: Sep 2017)b
PFS Enrollment ongoing
(Estimated primary completion: Jan 2016)
OS Enrollment completed
(Estimated primary completion: July 2015)
OS Enrollment ongoing
(Estimated primary completion: April 2016)
a Planned
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derived from 32 patients with RCC [37]. In a phase I
clinical trial, IMA901 was administered to 15 patients with
no prior treatment and 13 patients with multiple prior
therapies. At a 3-month benchmark, one partial response
(PR) was recorded along with 11 patients with stable
disease (SD). Limited toxicities were observed in this
initial experience, and correlative studies identified a
greater clinical benefit rate amongst patients that elicited
a more potent immune response to TUMAPs. A phase II
experience of IMA901 was subsequently conducted,
exploring IMA901 monotherapy or IMA901 preceded by a
single dose of cyclophosphamide. The latter arm explores
the hypothesis that “immune priming” with cyclophos-
phamide may reduce regulatory T-cell (Treg) populations.
Ultimately, it was found that cyclophosphamide priming
significantly improved survival.
These studies have culminated in a phase III study
comparing sunitinib monotherapy to sunitinib with IMA901,
the latter arm including a single priming dose of cyclo-
phosphamide [38]. The study enrolled 320 treatment-naı¨ve
patients with mRCC who demonstrated favorable- or
intermediate-risk disease by Heng criteria. Patients in this
experience were randomized to the experimental and
control arm in a 3:2 fashion. While the study explored the
primary endpoint of OS, several secondary endpoints will
focus on correlative aims including characterization of im-
mune response.
A second vaccine therapy currently in late stage devel-
opment for mRCC is AGS-003, an autologous dendritic cell
vaccine. Generation of the vaccine involves harvesting
autologous tumor tissue, isolation of RNA and subsequent
electroporation of this RNA into dendritic cells [39]. The
resulting product is reinfused in the patient at several
timepoints. AGS-003 has been explored as both mono-
therapy and in combination with sunitinib. The latter study
included 22 patients with synchronous metastatic disease
who had received cytoreductive nephrectomy. All patients
in this experience had either intermediate-risk disease
(71%) or poor-risk disease (29%) by Memorial Sloan Kettering
Cancer Center (MSKCC) criteria. Patients received one
cycle of sunitinib followed by 5 doses of AGS-003 every 3
weeks. The observed OS in the overall study population was
30.1 months, well in excess of the projected survival of 15
months estimated by existing nomograms. In particular,
those patients with an increase in memory T-cells were
noted to have prolonged survival [40].
The phase III ADAPT trial will compare sunitinib mono-
therapy to sunitinib with AGS-003 in a total of 450 patients
with synchronous mRCC [41]. The study aims to achieve a
roughly 30% improvement in survival with the addition of
AGS-003 as compared to sunitinib monotherapy. Patients
will be stratified by the number of adverse risk factors they
possess according to the Heng prognostic criteria [42]. It is
estimated that the study will complete accrual in 2015.
Outside of vaccines, other immunotherapeutic ap-
proaches may potentially alter current first-line treatment
algorithms for mRCC. Increasing attention has been focused
on the programmed death-1 (PD-1) signaling pathway. PD-1,
expressed on the surface of the activated T-cell, may bind
to one of two ligands, PD-L1 or PD-L2, on the surface of the
antigen presenting cell [43]. Association of these receptorsleads to T-cell anergy and diminution of the antitumor
immune response e a so-called “immune checkpoint”. As
monotherapy, the PD-1 inhibitor nivolumab is being
explored in a phase III registration trial comparing the
agent to everolimus in patients that have received 1e2
prior anti-angiogenic therapies [44]. The study has
completed accrual, and results are anticipated in 2015.
Although phase II studies of nivolumab suggest modest
response rates (roughly 20% across recently reported
studies), higher activity has been seen with nivolumab in
combination with a distinct checkpoint inhibitor, ipilimu-
mab [45,46]. A phase I study combining two dosing regimens
of nivolumab with ipilimumab in 44 patients showed
response rates of 29%e39% [47]. Notably, 77% of patients in
this experience had received prior treatment. These
impressive data prompted announcement of a phase III
study exploring the combination of nivolumab with ipili-
mumab in the front-line setting.
Several other checkpoint inhibitors under development
also show promise in mRCC. In a phase I expansion study,
MPDL3280A (a PD-L1-directed monoclonal antibody) was
administered in 53 patients with mRCC [48]. Of these pa-
tients, 83% had received prior therapy. Amongst 47 evalu-
able patients, a response rate of 13% was observed with a
24-week PFS of 53%. Based on the encouraging efficacy and
limited toxicity associated with the agent, a randomized
phase II study has emerged including three treatment arms:
(1) MPDL3280A monotherapy, (2) sunitinib monotherapy,
and (3) MPDL3280A with bevacizumab [49]. The study will
include a total of 150 patients with treatment-naı¨ve mRCC,
and will explore the primary endpoint of PFS. Crossover
onto the combination therapy arm is allowed for patients
receiving monotherapy with either MPDL3280A or sunitinib.
If data from this study is encouraging, a phase III study
exploring this combination is foreseeable.
While there is no doubt that a resurgence of immuno-
therapy has occurred in recent years, there is still sub-
stantial interest in targeted therapies acting upon other
axes. The dual VEGFR2/MET inhibitor cabozantinib has
shown substantial activity in a phase I trial including heavily
pre-treated patients with mRCC [50]. Amongst 25 patients
with a median of 2 prior lines of therapy, a median PFS of
12.9 months was observed. A registration trial is currently
underway comparing cabozantinib to everolimus in patients
with prior VEGF-directed therapy [51]. In the first-line
setting, an Alliance-led phase II trial will compare suniti-
nib and cabozantinib. The study will accrue a total of 150
patients and explore the primary endpoint of PFS [52]. A
positive outcome could warrant further exploration of
cabozantinib as initial therapy for mRCC.4. Conclusion
With the rapid evolution of targeted therapies and other
novel compounds for RCC, the practicing urologist faces a
number of important challenges. In the coming years, it will
be critical to follow the adjuvant literature carefully. With
multiple trials either recently completed or still underway,
there is substantial potential for VEGF-TKIs and mTOR in-
hibitors to migrate from the setting of metastatic disease to
the adjuvant space. Similar attention should be given to the
24 S.K. Pal et al.literature pertaining to cytoreductive nephrectomy.
Although the preponderance of studies seem to indicate
that the benefit of cytoreductive nephrectomy is main-
tained in the targeted therapy era, prospective studies such
as the CARMENA trial will more firmly establish the role of
this modality. Finally, the urologist should be intimately
aware of emerging systemic treatments for mRCC, many of
which have a foreseeable path into the front-line setting.
Some of these therapies (e.g., AGS-003, a vaccine derived
from surgically excised tumor tissue) may require a multi-
disciplinary approach for administration.
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